Publicaciones en colaboración con investigadores/as de Hospital del Bierzo (15)

2015

  1. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

    Rheumatology International, Vol. 35, Núm. 12, pp. 2069-2078

2014

  1. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis

    BioMed Research International, Vol. 2014

  2. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 231-236

  4. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 218-224

  5. IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

    BioMed Research International, Vol. 2014

  6. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 5, pp. 640-646

  7. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-Alpha therapy have higher TRAIL levels than controls: A potential compensatory effect

    Mediators of Inflammation, Vol. 2014

2013

  1. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 3, pp. 365-371

  2. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 532-537

  4. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 5, pp. 749-755

  5. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 6, pp. 913-918

  6. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 538-545

2012

  1. TNF-alpha antagonist therapy improves insulin sensitivity: In non-diabetic ankylosing spondylitis patients

    Clinical and Experimental Rheumatology, Vol. 30, Núm. 6, pp. 850-855